Background Although cannabis use after a fi rst episode of psychosis has been associated with relapse, little is known about the determinants of this most preventable risk factor for relapse of psychosis. Here we aimed to study whether the eff ects on outcome vary depending on the type of cannabis consumed and usage pattern.
Introduction
In the past 30 years, fi ndings of studies have shown that cannabis use is a contributory cause of psychotic disorders, especially if used often and initiated at an early age. 1, 2 Cannabis remains the most commonly used illicit drug in patients with established psychosis 3 and use is especially high in young people presenting with their fi rst episode of psychosis. 4 Only a few patients with established psychosis start using cannabis after onset of psychosis, 5 but a major concern is the substantial proportion who continue using the drug. 6 Findings of a recent meta-analysis suggest that continued cannabis use after the onset of psychosis predicts poor disease outcome as shown by a high number of relapses, admittance to hospital, and more severe positive symptomatology. 7 These fi ndings are consistent with evidence that experimental administration of the key psychoactive ingredient in cannabis is associated with transient psychotic symptoms and cognitive impairments in healthy individuals and exacerbation of symptoms in patients with a pre-existing psychotic disorder. 8, 9 However, whether the association between cannabis use and worse outcome in pre-existing psychosis is causal has remained inconclusive 7 because prospective evidence so far has not always established that cannabis use actually preceded and was in reasonable temporal proximity to the outcome of interest (ie, relapse of psychosis). More importantly, how parameters of cannabis use, such as type and potency of cannabis used and frequency of use, aff ect outcome has remained unclear. This gap in the scientifi c literature is especially important in view of fi ndings that dose, type, and pattern 10 of cannabis use are important determinants of its eff ect on onset of psychosis. In particular, for such evidence to be translated into real world meaningful solutions in the clinical setting, it is important to develop a more nuanced understanding of the association between one of the most potentially preventable risk factors of psychosis-ie, cannabis use and its determinants and the risk of relapse in psychosis.
Understanding the role of cannabis in relapse of psychosis is important not just because prevention of relapse is crucial for improved long-term outcome in psychosis, 11 but also because of the substantial fi nancial implications associated with need for hospital care in those who relapse; 12 up to 50% of fi rst-episode psychosis patients experience a relapse that results in hospital admission within the fi rst 2 years of illness, with the risk increasing to more than 80% by the eighth year. 13 Here we investigate the eff ects of continued cannabis use on risk of relapse as indexed by hospital admission over the fi rst 2 years after the onset of psychosis.
Methods

Participants
We recruited patients with fi rst-episode non-organic (non-aff ective [ICD10 codes F20-F29]) or aff ective [F30-F33]) psychosis, 14 aged 18-65 years who had been admitted to psychiatric services in South London, London, UK. Participants were assessed twice, fi rst close to the onset of their illness using face-to-face interviews and subsequently for follow up, using either a face-to-face or a telephone interview (if the individual was unable to attend interviews in person). Data from clinical records regarding hospital admissions were collected for participants who refused to take part in the follow-up interview (n=133) during the 2 years after psychosis onset. The study was approved by South London and Maudsley NHS Foundation Trust and Institute of Psychiatry Local Research Ethics Committee. All participants included in the study gave written informed consent.
Outcomes
We assessed cannabis use with a modifi ed version of the Cannabis Experience Questionnaire (CEQ mv ), 10 and collected data for premorbid cannabis use, and use in the fi rst 2 years after onset of psychosis. Cannabis users were classifi ed into diff erent cannabis use profi les based on their pattern of use depending on continuity and frequency of cannabis use after onset of psychosis. Type of cannabis (hash-like vs skunk-like) used was assessed by asking participants to describe their preferred type of cannabis. Based on this information, grouping was done in the same way as reported previously, 10 Information about service use, number, duration and legal status (voluntary or involuntary) of inpatient admissions, referral to crisis intervention team or standard treatment by a community mental health team was obtained from electronic patient records using established methods (appendix). Relapse was defi ned as admission to a psychiatric inpatient unit because of exacerbation of psychotic symptoms within 2 years of fi rst presentation to psychiatric services and diagnosis of psychosis. If the patient was admitted to hospital upon fi rst presentation to psychiatric services with a diagnosis of psychosis, this
Research in context
Evidence before this study In January, 2016, we published a meta-analysis in The Lancet Psychiatry, wherein we studied the eff ect of continued cannabis use on the risk of relapse in patients with psychosis. In this meta-analysis, we searched MEDLINE for articles published in any language until April, 2015, using a combination of search terms for describing the exposure (cannabis use), the outcome of interest (relapse of psychosis), and the study population (patients with psychosis). Data were pooled together from 24 studies (16 565 participants) to compare relapse outcomes in the following groups: continued cannabis users, discontinued cannabis users, and non-users. Continued cannabis users had more relapses and longer stays in hospital compared with non-users. These adverse eff ects were not recorded in patients who discontinued cannabis use after the onset of psychosis. An update of the search (April 11, 2016, 129 included studies) identifi ed two additional studies (appendix p 4), which confi rmed an increased risk for relapse related to cannabis use in fi rst episode psychosis and hospital admissions in patients with established schizophrenia.
Added value of this study
Our fi ndings add to the evidence on cannabis use and relapse in psychosis. For the fi rst time, we used a detailed assessment of distinct cannabis use profi les in a large sample of fi rst episode psychosis patients and showed that the eff ect on outcome varies depending on the type of cannabis consumed as well as usage pattern, after controlling for a range of important confounders previously not generally considered (eg, medication adherence or other illicit drug use). The results were validated for covariate adjustment (by using propensity score matching) and consistency (by using diff erent measures of relapse, including risk and number of relapses, length of relapse, time until relapse, severity of relapse), and point towards potential targets for intervention.
Implications of all the available evidence
Continued cannabis use (at least monthly use) after the onset of psychosis, especially use of high-potency cannabis, is associated with a signifi cantly worse outcome in individuals with fi rst episode psychosis. In our study, outcomes were better in those who used cannabis in smaller doses (reduced frequency, lower potency, and shorter duration of continuation) after onset, which suggests that interventions should aim to reduce frequency of use or shift to less potent forms of cannabis when complete cessation of cannabis use might not be a realistic goal.
See Online for appendix was not considered as a relapse event. Alcohol use, other illicit drug use, and cigarette use, care intensity at onset (as a proxy measure of illness severity based on a rating of intensity of service use for each subject at onset; appendix p 7), and medication adherence were assessed and included in the analysis as potential confounders based on previous scientifi c literature. The appendix describes estimated measure ments of cannabis use, relapse, and confounders.
Statistical analysis
Data analysis was done with R. We modelled follow-up data for 2 years after the onset of psychosis for every participant. The cannabis profi le variable was coded as an ordered categorical variable, with the former (regular) user group acting as the reference group (appendix). First, exploratory simple analyses, including χ² test for categorical variables and Kruskal-Wallis test and Mann-Whitney U (two-sided) test for continuous outcomes were used to compare the diff erent cannabis use groups. Following common practice, 2 we generated Kaplan-Meier curves and compared the diff erent cannabis use groups using logrank tests. Pairwise comparisons were adjusted with Bonferroni correction to account for multiple testing. Multiple logistic regression analyses were employed to compute the odds ratio (OR) and 95% CIs, using binary logistic regression for binary outcomes (risk of relapse) and ordinal logistic regression analysis for ordered categorical outcome (care intensity at follow up). We used multiple negative binominal regression models for continuous outcomes (number of relapses, length of relapse, time to relapse; appendix). Sensitivity analysis was done by calculating propensity scores to validate the results and to address the limitations by confounding adjustment in regression analysis (appendix). 15 We included antipsychotic medication adherence in a separate regression model because these data were available for only a subset of cases, considering that antipsychotic medications were not prescribed for all participans after the onset of illness.
Role of the funding source
The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. All authors have approved the fi nal version of the paper.
Results
Between April 12, 2002, and July 26, 2013, we recruited 256 fi rst episode psychosis patients and did follow-up assessments until September, 2015. The two groups (completers and refusers) did not diff er signifi cantly in their risk of relapse (36% vs 38% relapsed, χ²= 0·15; p=0·70) and baseline characteristics (appendix p 6 (table 1) . By contrast, low-frequency and high-frequency users of high-potency (skunk-like) cannabis were more likely to experience compulsory admissions than former cannabis users (29% and 38% vs 7%). We noted an eff ect of pattern of cannabis use on number of relapses (p=0·01), length of relapses (p=0·009), time to relapse (p=0·02), and care intensity (p=0·005; table 2). Kaplan-Meier curves suggested that the diff erent groups signifi cantly diff ered with regard to their time to relapse (Kaplan-Meier p=0·007). High-frequency and skunk-like users were more likely to have an earlier relapse than the former (regular) user group (KaplanMeier with Bonferroni correction p=0·006; fi gure).
In multiple logistic regression analysis, continued high-frequency use of high-potency cannabis (indexed as at least daily use throughout the follow up) remained a signifi cant predictor for relapse (OR 3·28; 95% CI 1·22-9·18) when compared with former users (table 3) . The eff ect remained signifi cant when medication nonadherence was included in the model (OR 2·73; 95% CI 1·02-7·56), although this eff ect was reduced in magnitude when compared with the odds from simple logistic regression analysis (OR simple 4·37; 95% CI 1·72-11·85). None of the other cannabis groups were diff erent in their risk of relapse when compared with former users. In those risk models, only three other predictors remained signifi cant, including non-white ethnic origin, care intensity at onset, and antipsychotic medication non-adherence (table 3) . The results from the other multiple regression analyses confi rmed that the adverse eff ects of continued high-frequency skunklike use were also evident on the number of relapses, time to relapse, and a higher care intensity at follow up, while controlling for the above confounders. Including medication adherence into the model did not substantially change the results, although high-frequency skunk-like use remained a signifi cant predictor only for length of relapse in this model ( considering all covariates (appendix), the eff ect of highfrequency skunk-like use was reduced in its magnitude but remained a signifi cant predictor for risk of relapse and care intensity at follow up. Several other predictors were signifi cantly linked to relapse in the multiple regression analyses (table 3) . Ethnic origin and medication non-adherence remained signifi cant predictors in all models, including risk of relapse, number and length of relapses, time to relapse, and care intensity at follow up. Number of relapses was predicted by cigarette use and other illicit drug use. Finally, higher care intensity at onset was associated with risk of relapse, an increase in number of relapses and increase of length of relapse, as well as a higher care intensity throughout the 2 years following the onset of illness.
Further analyses using the continued user group (skunk-like/high-frequency) as the reference group showed that this group relapsed earlier than did the continued user (hash-like; b=0·29; 95% CI 0·01-0·58) and continued user (skunk-like/low frequency; b=0·27, 95% CI 0·06-0·48) and never (regular) user groups (b=0·21, 95% CI 0·04-0·39; appendix).
Discussion
For the fi rst time, this study of outcome in patients after their fi rst episode of psychosis investigated the eff ect of diff erent patterns of cannabis use on risk of relapse by incorporating information about continuation, frequency, and type of cannabis used. Our results suggest that eff ects of cannabis use on outcome vary, depending on specifi c Reference group refers to former (regular) users. OR=odds ratio. IRR=incidence rate ratio. *Medication non-adherence not included as a covariate. †Estimated from multiple logistic regression analysis. ‡Estimated from negative binomial regression. §Coeffi cient estimate from negative binomial regression. ¶Estimated from multiple ordinal regression analysis. ||Only medication non-adherence included as a covariate. cannabis use profi le. Whereas former regular cannabis users who stopped using the substance regularly after the onset of psychosis had the lowest risk of relapse, those who continued to use at least on a monthly basis were most likely to experience a relapse. More specifi cally, continued users of high-potency (skunk-like) cannabis who were using on a daily basis had the highest risk of relapse of psychosis when compared to former cannabis users. This eff ect was independent of other putative risk factors for poor outcome, including ethnic origin, sex, age of onset, alcohol, cigarette and illicit drug use, and care intensity at onset (appendix). Furthermore, highfrequency skunk-like users had more relapses, longer durations of hospital stay, shorter times to relapse, and more severe (as indexed by care intensity at follow up) relapses, when compared with former users. More rigorous adjustment for confounders using propensity score matching showed similar results, with highfrequency users having a 1·9 times higher risk of relapse of psychosis. This eff ect is similar in its magnitude, albeit in the opposite direction, to the eff ect of antipsychotic medication treatment on risk of relapse in psychosis (eg, 2·4 times higher risk for placebo vs drug-treated patients 16 ). High-frequency skunk-like users also relapsed earlier than hash-like and low-frequency skunk-like continued cannabis users and never (regular) users. Together, these results extend previous observational 2, 17 and experimental evidence 9 of dose-response eff ects of cannabis in patients with psychosis to demonstrate that the eff ects of cannabis use on outcome in psychosis depend on the type of cannabis consumed as well as frequency of use. This fi nding is consistent with similar evidence on the onset of psychosis. 10 High-potency cannabis has become dominant in the UK. 18 It has higher levels of delta-9-tetrahydrocannabiniol (THC), the main psychotogenic ingredient in cannabis, which modulates the neural substrates implicated in psychosis. 8, 19 Furthermore, high-potency cannabis has minimal concentrations of cannabidiol (CBD), 18 which ameliorates some of the eff ects of THC 20 and might have antipsychotic properties. 21 High relapse rates and short time to relapse in high-frequency skunk users might be the result of a failure to respond to antipsychotic treatment 4 either on its own or in combination with an increase in the severity of psychotic symptoms in those frequently exposed to a higher dose of THC, 9 which were not investigated in the present study. This result might explain why some previous studies that did not diff erentiate between the type of cannabis did not report an association between cannabis use and relapse. 22 It might also explain why the risk estimate noted in our study for the high-dose group (high-frequency/skunk-like) was substantially higher compared with the pooled odds from previous studies that investigated the risk of cannabis on relapse (OR simple 4·37 vs OR simple 1·97). 7 The fi nding of no diff erence in outcome between cannabis users who remained abstinent after the onset of psychosis and the non-user group suggests that the eff ects of previous cannabis use on outcome in psychosis are not irreversible 7 and that investigations need to move beyond the eff ects of lifetime cannabis use or cannabis use assessed at onset only. 23 Future investigations should focus on changes in pattern of use and type of cannabis used after psychosis onset because these might be the key factors driving adverse outcomes associated with cannabis use in patients with psychosis.
Our data suggest that high-frequency use of potent forms of cannabis will adversely aff ect outcome even in treatment-adherent patients, perhaps by reducing the eff ectiveness of antipsychotics. 3 Together, these results are opposed to non-causal explanations for the association between frequent (daily) use of high-potency skunk-like cannabis and outcome, such as reverse causation or confounding, and suggest that change in cannabis use after the onset of psychosis is an important determinant for outcome in psychosis. In view of the lack of eff ective psychological 24 or pharmacological 25 treatments for comorbid cannabis users with psychosis, our results suggest that reducing frequency of use or shifting to less potent forms might be useful intervention strategies in psychotic patients who are otherwise unable to stop using cannabis.
This study has certain limitations, such as comprising a selective subset of inner city, fi rst episode of psychosis patients more likely to engage with community mental health services and having less severe psychopathology, bias from refusal to take part in the study, use of retrospective self-report measures of cannabis and other substance use leading to under-reporting, modest sized (n=8) continued hash-like (resin) user group, and not controlling for the eff ect of migrant status, or the eff ect of type and dose of antipsychotic medication on relapse. However, as discussed in greater detail in the appendix, these factors are unlikely to have aff ected the direction of our results.
Nevertheless, this is the fi rst study that suggests that those who continue to use high-potency cannabis even after the onset of their psychosis are at the greatest risk of relapse of their illness and of experiencing more frequent and earlier relapses that require more intensive psychiatric care than those who do not continue cannabis use.
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